Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer Inc

Looking for Value Stocks to Add to Your Portfolio? Here are 5 For Your List

Heightened inflationary pressure, deepening supply chain disruptions, and the possibility of aggressive interest rate hikes later this year have fostered a volatile stock market. Because these factors are not expected to abate anytime soon, we think investors looking to generate solid long-term returns could consider betting on the stocks of…

StockNews.com

Pfizer's COVID pill is poised to be among the fastest-selling treatments of all time

Demand for Covid pills is set to make Pfizer Inc.’s Paxlovid among the fastest-selling treatments of all time, with revenue of almost $24 billion expected in 2022, according to a forecast from analytics group Airfinity Ltd.

Tribune News Service

Read Why Demand For Pfizer's COVID-19 Antiviral Therapy Is Unexpectedly Low: Reuters

Global demand for Pfizer Inc's (NYSE: PFE) Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer/BioNTech Fourth COVID-19 Vaccine Dose Protects Against Omicron For At Least One Month

A fourth dose of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) provided significant protection against severe disease, hospitalization, and death for at least a month i

Benzinga

Two long COVID Patients Recover After Pfizer's Therapy; Side Effects, Safety Needs To Be Assessed: Reuters

Reuters reported that two patients found relief from long COVID after taking Pfizer Inc's (NYSE:PFE) antiviral Paxlovid, including a researcher who tested it on herself. Long COVID is estimated to affect up to 30% of people infected with the coronavirus. It can last for months. More than 200 symptoms have been associated with the…

Benzinga

Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report

Japan's health ministry panel authorized a plan to approve Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine, which is set to be the fourth such vaccine to be approved in Japan. It will be available for first and second shots with an interval of three weeks. The Novavax product is a recombinant protein vaccine that uses…

Benzinga

Pfizer says third COVID shot boosts antibodies in kids 5 to 11

Pfizer Inc. and BioNTech SE said a third dose of their COVID vaccine increased antibodies against the omicron strain by 36-fold in a clinical trial.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from a Phase 2/3 trial of a 10 µg booster (third) dose of COVID-19 vaccine in children aged 5-11 years.

Benzinga

Pfizer/BioNTech say booster dose increases protection vs Omicron in kids aged 5-11

A third dose of the COVID-19 vaccine from Pfizer Inc and BioNTech produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on Thursday.

Reuters

Japan-Based Shinogi's COVID-19 Drug Associated With Birth Defects: Bloomberg

Shionogi & Co stock slumped 16% in Tokyo after preclinical studies showed its experimental COVID-19 drug disturbed fetal development, triggering concerns about its approval. Kyodo News reported that the drug likely wouldn’t be recommended for pregnant women without giving attribution. The animal data, which showed harm when given at high doses, was…

Benzinga

What's Going On With Myovant Sciences Stock Today?

Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on the Supplemental New Drug Application for MYFEMBREE for the manag

Benzinga

5 Global Healthcare Stocks to Buy as BofA Warns of a "Recession Shock"

The healthcare industry is well-positioned to ride out a potential recessionary shock, thanks in-part to the inelastic demand for COVID-19 vaccines worldwide. Thus, we think investors could invest in fundamentally sound healthcare stocks Pfizer Inc. (PFE), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Eli Lilly and Company (LLY), and Merck…

StockNews.com

What's Going On With Pfizer Stock Today?

Pfizer Inc (NYSE: PFE) shares are trading higher Thursday. The company announced the acquisition of ReViral for a total consideration of up to $525 million.

Benzinga

Europe Holds Second COVID-19 Booster Dose For People Aged Under 80 Years

European Medicines Agency concluded that it is too early to consider using the fourth dose of either Pfizer Inc (NYSE:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Pfizer Beefs Up Its RSV Antiviral Portfolio With $525M ReViral Acquisition

Pfizer Inc (NYSE: PFE)

Benzinga

Pfizer/BioNTech's Second COVID-19 Vaccine Booster Provides Short-Lived Protection In Elderly, Israel Study Shows

An Israel-based study has found that a fourth dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) vaccine lowered rates of COVID-19 infection among the elderly.

Benzinga

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

Benzinga

Pfizer/BioNTech's COVID- Vaccine Cuts Hospitalization Risk In Kids Aged 5-11 Years: Reuters

According to a US-based study, children ages 5 to 11 who received the Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine were 68% less likely to be hospitalized during the omicron wave than unvaccinated children. Adolescents aged 12-18 who received two shots of the vaccine were around 40% less likely to be hospitalized with the…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why BioNTech Shares Are Surging Today

BioNTech SE (NASDAQ:BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE:PFE) delivered approximately 2.6 billion doses of Comirnaty/BNT162b2 worldwide in 2021, including over 1 billion doses to low- and middle-income countries. As…

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Benzinga

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. The regimen…

StockNews.com

3 Healthcare Stocks to Buy for the Long Run

The healthcare industry has achieved significant growth over the past two years in-part because the COVID-19 pandemic fostered a stream of hefty private and federal investments in the sector. With accelerating advancement and increased tech integration in healthcare, we expect renowned companies Pfizer Inc. (PFE), Merck & Co., Inc. (MRK),…

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

Benzinga

Pfizer's Second Etrasimod Phase 3 Ulcerative Colitis Trial Hits Primary Goal

Pfizer Inc (NYSE:PFE) has announced topline results from a second Phase 3 study of etrasimod for moderately to severely active ulcerative colitis (UC). The 12- and 52-week ELEVATE UC 52 follow the recent announcement of 12-week findings from the ELEVATE UC 12 trial. In this 52-week study, also known as ELEVATE UC 52,…

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.